Abstracts tagged "Gene Expression"

Abstract Number: 0032 • ACR Convergence 2020
A Prospective, Multicenter, Clinical Performance Evaluation Study for an in-vitro Diagnostics Medical Device (PREDYSTIC® Infliximab RA) for Prediction of Infliximab Responsiveness in the Treatment of Rheumatoid Arthritis
Miklos Sebeszta¹, Katalin Tauberne Jakab¹, Tamas Ponyi¹, Gyula Poor², Zsolt Hollo¹, Laszlo Szilagyi¹, Emese Kiss² and Gabor Zahuczky³, ¹Egis Pharmaceuticals, Budapest, Hungary, ²ORFI, Budapest, Hungary, ³UD Genomed, Debrecen, Hungary
Background/Purpose: Approximately 30-40% of RA patients fail to respond to first biological therapy. Predicting the patient’s responsiveness to the first biological therapy is still an…
Abstract Number: 1039 • ACR Convergence 2020
Tofacitinib as a Steroid-sparing Therapy in Pulmonary Sarcoidosis: Two Prospective Cases and Molecular Analysis
Marcia Friedman¹, Stevens Janelle², Julianna Desmarais³, Daniel Seifer³, Brian Le³, Kimberly Ogle³, Christina Harrington³, Peter Jackson⁴, Dongseok Choi³ and James Rosenbaum³, ¹Oregon Health and Science University, Portland, OR, ²Tuality Healthcare, Hillsboro, OR, ³Oregon Health & Science University, Portland, OR, ⁴Johns Hopkins University, Baltimore, MD
Background/Purpose: Patients with pulmonary sarcoidosis often require prolonged corticosteroids to treat their disease. There are currently no FDA approved steroid-sparing therapies for sarcoidosis. We report…
Abstract Number: 1933 • ACR Convergence 2020
Small Vessel Vasculitis Surrounding a Preserved Temporal Artery: Search for Tissue Biomarkers with Potential Diagnostic Value
Georgina Espígol-Frigolé¹, Roser Alba-Rovira², Salvador Naranjo-Suárez³, Magda Terenas⁴, Sergio Prieto-González¹, Marc Corbera-Bellalta³, Javier Marco-Hernández⁴, Marco A. Alba¹, Farah Kamberovic³, Roberto Ríos-Garcés¹, Jose Hernández-Rodríguez¹ and Maria C. Cid¹, ¹Vasculitis Research Unit, Department of Systemic Autoimmune Diseases, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Barcelona, Catalonia, Spain, ²Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, IRB-CELLEX. Institut d’Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona, Spain, Barcelona, ³IDIBAPS, Barcelona, Spain, ⁴Hospital Clinic Barcelona, Barcelona, Spain
Background/Purpose: Systemic vasculitides are complex and heterogeneous diseases with overlapping features that frequently pose a diagnostic challenge to clinicians. The temporal artery biopsy (TAB) is…
Abstract Number: 0033 • ACR Convergence 2020
Pre-pregnancy Long Non-coding RNA Expression Signatures Among Women with Rheumatoid Arthritis Who Improve or Worsen During Pregnancy
Matthew Wright¹, Mette Kiel Smed², J Lee Nelson³, Jørn Olsen⁴, Merete Hetland⁵, Vibeke Zoffmann² and Damini Jawaheer⁶, ¹UCSF Children's Hospital Oakland Research Institute, Oakland, CA, ²The Juliane Marie Center, Copenhagen, Denmark, ³Fred Hutchinson Cancer Res Ctr and U of WA, Seattle, WA, ⁴Aarhus University Hospital, Aarhus, Denmark, ⁵The DANBIO Registry, Rigshospitalet, Glostrup, Denmark, ⁶UCSF Benioff Children's Hospital Oakland Research Institute, Oakland, CA
Background/Purpose: Pregnancy is known to have disease-modifying effects on rheumatoid arthritis (RA). A role for long non-coding (lnc) RNAs in the improvement or worsening of…
Abstract Number: 1121 • ACR Convergence 2020
Osteoarthritis in the Million Veterans Program: Integrating the Electronic Medical Record with Precision Medicine
Merry-Lynn McDonald¹, Preeti Lakshman Kumar¹, Vinod Srinivasasainagendra¹, Joshua Richman¹, Sarah Pinson¹, Alison Rocco¹, Dennis Richard², Vivek Jagadale², Cynthia Brown¹, Hemant Tiwari¹, Jasvinder Singh³ and Marcas Bamman¹, ¹University of Alabama at Birmingham, Birmingham, ²Central Arkansas Veterans Healthcare System, Little Rock, ³University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Osteoarthritis (OA) had profound impacts on societal and patient-centered outcomes, including disability. As the first step to leverage the rich resource of the Million…
Abstract Number: 1956 • ACR Convergence 2020
Dysregulated Expression of the Long Non-coding RNA, LINC01871, Implicated in Sjögren’s Syndrome Pathogenesis
Michelle Joachims¹, Bhuwan Khatri¹, Kandice Tessneer², Anna Stolarczyk¹, Graham Wiley¹, Astrid Rasmussen¹, Joel Guthridge¹, Judith James³, R. Scofield¹, Kathy Sivils¹, Indra Adrianto⁴ and Christopher Lessard¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK, ⁴Henry Ford Health System, Detroit, MI
Background/Purpose: Sjögren’s syndrome (SS) is an autoimmune disease characterized by inflammatory destruction of the exocrine glands. Long non-coding RNAs (lncRNAs) are a functionally diverse class…
Abstract Number: 0034 • ACR Convergence 2020
Gene Expression Signatures in C-Reactive Protein High and Low Rheumatoid Arthritis
Adam Cornish¹, Kristin Wipfler¹ and Kaleb Michaud², ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Transcriptome profiling has expanded our ability to identify biomarkers and therapeutic targets and better understand disease progression in a wide variety of conditions. Serum…
Abstract Number: 1154 • ACR Convergence 2020
Distinct Gene Signature Predicts Strong Clinical Responses to Canakinumab in Children with Systemic Juvenile Idiopathic Arthritis
Emely Verweyen¹, Alex Pickering², Alexei Grom³ and Grant Schulert⁴, ¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Harvard Medical School, Boston, MA, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: Canakinumab is a human anti-IL1β blocking agent that effectively neutralizes IL1β mediated signaling and is used to treat diseases such as systemic juvenile idiopathic…
Abstract Number: 1968 • ACR Convergence 2020
Cathepsin S Gene Expression Measured in the Peripheral Blood of Osteoarthritic Patients Prior to Surgery as a Biomarker of Post-operative Pain Development
Elena Tchetina¹, Kseniya Glemba¹, Galina Markova¹, Maksim Makarov¹ and Aleksandr Lila¹, ¹Nasonova Research Institute of Rheumatology, Moscow, Russia
Background/Purpose: Osteoarthritis (OA) is a chronic rheumatic disease, which involves pain, limited inflammation, and local destruction of the knee joint. OA pain is a major…
Abstract Number: 0037 • ACR Convergence 2020
Lipoprotein-associated Phospholipase A2: A New Biomarker for Lymphoma Development in Sjögren’s Syndrome
Adrianos Nezos¹, Eleni Kotsifaki¹, Charalampos Skarlis², Konstantinos Markakis¹, Haralampos Moutsopoulos³, Michael Koutsilieris¹, Clio Mavragani¹ and Anna Psarrou¹, ¹National & Kapodistrian University of Athens, Athens, Greece, ²National &Kapodistrian University of Athens, Athens, Greece, ³National & Kapodistrian University of Athens/ Academy of Athens, Athens, Greece
Background/Purpose: B-cell non-Hodgkin's lymphoma (B-NHL) is one of the major complications of primary Sjögren’s syndrome (SS). Chronic inflammation and macrophages in SS minor salivary glands…
Abstract Number: 1212 • ACR Convergence 2020
Whole Blood Transcriptional Changes Following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in MTX-Naïve Adults with Moderately-to-Severely Active Rheumatoid Arthritis (RA)
Peter Taylor¹, Bryan Downie², Emon Elboudwarej², Sam Kim², Angie Hertz², Amer Mirza², Jeff Siegel³, Rachael Hawtin² and Jinfeng Liu², ¹Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Gilead Sciences, Inc., Foster City, ³Gilead Sciences, Inc., Foster City, CA
Background/Purpose: Filgotinib (FIL), a selective, oral JAK1 inhibitor, has shown efficacy and safety in phase 3 studies in adults with moderately-to-severely active RA. Previously, we…
Abstract Number: 2007 • ACR Convergence 2020
Whole Blood Transcriptional Changes Following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in Adults with Moderately-to-Severely Active Rheumatoid Arthritis with Prior Inadequate Response to Methotrexate
Peter Taylor¹, Bryan Downie², Emon Elboudwarej², Sam Kim², Angie Hertz², Amer Mirza², Jeff Siegel³, Rachael Hawtin² and Jinfeng Liu², ¹Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Gilead Sciences, Inc., Foster City, ³Gilead Sciences, Inc., Foster City, CA
Background/Purpose: Filgotinib (FIL), a selective, oral JAK1 inhibitor, has shown efficacy and safety in phase 3 studies in adults with moderately-to-severely active rheumatoid arthritis (RA).…
Abstract Number: 0040 • ACR Convergence 2020
Whole Blood RNA Expression in Clinically Suspected Arthralgia Patients Shows a Potential Value in Prediction of Inflammatory Arthritis
Ellis Niemantsverdriet¹, Erik van den Akker¹, Debbie Boeters¹, Susan van den Eeden¹, Annemieke Geluk¹ and Annette van der Helm - van Mil², ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: Rheumatoid arthritis (RA)-patients have differently expressed genes involved in cytokine/chemokine-mediated immunity compared to healthy controls, which are changed years before RA-diagnosis. It is unclear,…
Abstract Number: 1225 • ACR Convergence 2020
Targeting to IL-6 or Specific JAKs for RA Treatment: Seeking a Rationale for Switching Each Other If One of These Treatments Resulted in Lack of Efficacy
Yoshinobu Koyama¹, Yoshiharu Sato², Hiroshi Iijima², Moe Sakamoto³ and Toshie Higuchi³, ¹Okayama Red Cross Hospital, Japanese Red Cross Society, Okayama, Japan, ²DNA Chip Research Inc, Tokyo, Japan, ³Division of Rheumatology, Okayama Red Cross Hospital, Japanese Red Cross Society, Okayama, Japan
Background/Purpose: Inhibition of IL-6 signaling is one of the most established strategies for RA treatment. Tocilizumab (TCZ) is the pioneer which blocks IL-6 signaling by…
Abstract Number: 2033 • ACR Convergence 2020
Large-scale Examination of Longitudinal Skin Gene Expression and Its Associations with Skin Thickness in Systemic Sclerosis
Brian Skaug¹, Marka Lyons¹, William Swindell², Gloria Salazar¹, Julio Charles¹, Connor Vershel¹, Maureen Mayes³ and Shervin Assassi³, ¹University of Texas Houston, McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ²The Jewish Hospital, Department of Internal Medicine, Cincinnati, OH, ³University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX
Background/Purpose: Numerous studies have revealed dysregulated gene expression in the skin of systemic sclerosis (SSc) patients, with varying degrees of inflammatory/immune and fibroblast upregulation. However,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].